Ulcerative colitis and Crohn’s disease are types of inflammatory bowel disease (IBD) that cause irritation and inflammation in the gastrointestinal tract (GI tract). The immune system attacks the GI ...

Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – AbbVie’s Humira – in severely active ulcerative colitis. The results are ...

Please provide your email address to receive an email when new articles are posted on . Entyvio therapy may improve disease course of immune-mediated diarrhea colitis and decrease steroid exposure, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . Entyvio yielded a lower risk for non-infectious serious adverse events than TNF antagonist therapy in Crohn’s ...

In May, the U.S. Food and Drug Administration (FDA) simultaneously approved Entyvio for the treatment of adults with moderately to severely active UC and CD. That same month, Entyvio was also granted ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Entyvio (vedolizumab) is a prescription drug that’s used to treat ulcerative colitis and Crohn’s disease. It’s not known whether Entyvio is safe to use while pregnant or breastfeeding. If you can ...

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor ...

Studies, presented at the 25th UEG Week, demonstrated the effectiveness of Takeda’s Entyvio in treating ulcerative colitis and Crohn’s disease, IBD News Today reports. From May 2014 to January 2017, ...